Epirubicin PhaRes 2 mg/ml (IV Infusion)
10 mg vial: ৳ 1,420.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Epirubicin hydrochloride |
| Company | Thymoorgan pharmazie gmbh germany |
Indications
- Adjuvant therapy
- Axillary node tumor involvement
- Breast cancer
Pharmacology
- Cytotoxic properties
- DNA and RNA synthesis inhibition
- Topoisomerase II cleavage
- DNA intercalation
- Plasma protein binding
- Metabolism by liver and other organs
- Biliary and urinary excretion
- Terminal elimination half-life
Dosage & Administration
- Intravenous infusion
- 3-to-4-week cycles
- Total dose administration options
- Recommended dose range
- Specific treatment regimens
- Prophylactic antibiotic therapy
Interaction
- Cardioactive compounds
- Cimetidine interaction
- Additive toxicity with cytotoxic drugs
- Paclitaxel and Docetaxel effects
- Radiation therapy interaction
- Hepatic function impact
Contraindications
- Hypersensitivity to Epirubicin or anthracyclines
Side Effects
- Myelosuppression
- Cardiotoxicity
- Alopecia
- Hyperpyrexia
- Lethargy
- Amenorrhoea
- Nausea
- Vomiting
- Diarrhea
- Fever
- Rash
- Anorexia
- Harmless reddish appearance of urine
Pregnancy & Lactation
- Pregnancy Category D
- Excretion in human milk
- Risk-benefit assessment for pregnancy and nursing
Precautions & Warnings
- Refrigerated storage precautions
- Visual inspection prior to administration
- Qualified physician supervision
- Baseline assessment before treatment
- Supportive care for myelosuppression
- Cardiotoxicity monitoring
Use in Special Populations
- Dosage adjustments for toxicities
- Bone marrow dysfunction considerations
- Hepatic and Renal impairment recommendations
- Pediatric, Geriatric use cautions
Overdose Effects
- Supportive treatment for overdose
- Delayed congestive heart failure observation
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Refrigerator storage
- Protect from light
- Keep out of the reach of children